Patent foramen ovale in older patients with cryptogenic stroke or transient ischaemic attack
A cryptogenic stroke is one that has eluded an explanation despite complete investigation aimed at uncovering a cause. Since 2003, six randomised trials have collected a large amount of data showing the benefit of patent foramen ovale (PFO) closure compared with standard medical therapy in young patients (aged 18-60 years) with cryptogenic stroke. However, new questions have now emerged concerning the best treatment for people older than 60 years. Traditionally, PFO-related stroke has been considered a disease of younger people, and excluded from the differential diagnosis in elderly patients. But this exclusion confuses incidence with prevalence estimates. In fact, factors that predispose people to paradoxical embolism (immobility, venous thrombosis, and hypercoagulability) increase with age, and it is probable that the incidence of PFOrelated stroke also increases. However, among patients with stroke, older people will have a lower prevalence of PFO-related strokes because of competing stroke mechanisms, such as lacunar disease, large artery atherosclerosis, and cardiogenic embolism. However, notwithstanding these coexisting mechanisms, older patients with PFO-related stroke might also benefit from PFO-specific therapy. It has been argued that diagnostic tests to establish the cause of stroke are only indicated if a new, active treatment decision is needed to change the management of a patient. But a physician's responsibility includes making accurate diagnoses, irrespective of what ends up on a prescription pad. An accurate diagnosis of PFO-related stroke informs recurrence risk (which is relatively low 1 ) and guides investigations and treatment later, if stroke recurs. The Risk of Paradoxical Embolism score can help to distinguish pathogenic from incidental PFOs. This score is applicable to older populations because it was derived from patients of all ages. Over the past year, the research interest in PFO has shifted away from debating the efficacy of closure and towards optimising patient selection. In The Lancet Neurology, Sara Mazzucco and colleagues 3 contribute to this shift by showing that screening for a right-toleft shunt (RLS) using contrast-enhanced transcranial Doppler (bubble-TCD) was feasible in 91% of a series of patients aged over 60 years with transient ischaemic attack or non-disabling stroke. Not surprisingly, the results are consistent with those seen in younger patients-the prevalence of PFO is significantly higher in patients with cryptogenic stroke than in patients with stroke of known cause.
The authors highlight the importance of distinguishing large from small PFOs. In principle, this distinction might be relevant for identifying pathogenic PFOs, for predicting stroke recurrence, or for selecting those patients that are more likely to benefit from closure. However, evidence on these issues is not clear. In the largest study of PFO size and relation to the index stroke, 4 PFO size was not correlated with its likelihood of pathogenicity. Confusingly, stroke recurrence might be increased by more than 3 times in patients with small PFOs compared to that in patients with large ones. Similarly, the effect of PFO closure has not been shown to be different for subgroups of patients with particular PFO characteristics, such as a large RLS or the coexistence of an atrial septal aneurysm. Based on first principles, patients in different subgroups might be expected to respond differently to PFO closure, but the data from randomised controlled trials are equivocal. Evidence from one trial 5 suggested heterogeneity but a second trial 6 seemingly did not. A third trial 7 did not suggest heterogeneity, although some researchers have pointed to the forest plots published in the trial as supporting it, overlooking the non-significant p interaction values. The significant point estimate seen in people with large RLS was almost identical to those with small RLS (which was not significant due to a wider CI). 7 Provocatively, the results for men compared with women in this trial show the same relationship (ie, a significant point estimate was seen in men, but not in women), but it would not be realistic to only treat men. 7 Therefore, reliance on the relevance of PFO characteristics for determining who should undergo closure is not yet evidence-based.
Mazzucco and colleagues 3 have shown that PFO is easily identifiable with bubble-TCD and overrepresented in older patients with cryptogenic stroke, which implicates PFO as a cause of stroke, even in patients older than 60 years. Treatment options for this
